Aging and Atherosclerosis Create Vicious Cycle That Accelerates Both Diseases

This groundbreaking review fundamentally reframes our understanding of the relationship between aging and atherosclerosis, revealing it as a bidirectional, self-perpetuating cycle rather than a simple cause-and-effect relationship. The research matters because cardiovascular disease remains the leading cause of death globally, and its intersection with aging affects virtually everyone as populations age worldwide.

The authors conducted a comprehensive analysis of existing literature to map the molecular mechanisms linking aging and atherosclerosis. They examined how chronological aging creates a pro-atherogenic environment through multiple pathways: endothelial dysfunction reduces nitric oxide availability, immune senescence promotes chronic inflammation, mitochondrial dysfunction increases oxidative stress, and stem cell exhaustion impairs vascular repair. Simultaneously, they investigated how atherosclerosis accelerates biological aging through chronic tissue hypoxia, systemic inflammation, and cellular senescence.

Key findings reveal that both processes share fundamental molecular hallmarks including the senescence-associated secretory phenotype (SASP), telomere shortening, mitochondrial dysfunction, and epigenetic modifications. The research shows that atherosclerotic plaques don't just result from aging—they actively accelerate systemic aging by promoting inflammaging, exhausting stem cell pools, and causing chronic hypoperfusion that damages high-metabolic organs like the brain, heart, and kidneys.

The implications are transformative for therapeutic development. Rather than treating aging and cardiovascular disease separately, this research suggests targeting shared pathways could address both simultaneously. Promising interventions include senolytics to clear senescent cells, anti-inflammatory agents, NAD+ supplementation to restore mitochondrial function, and therapies targeting the SASP. This "geroscience" approach could extend healthspan while reducing cardiovascular risk.

However, the review acknowledges limitations including the need for more clinical validation of proposed mechanisms and the challenge of translating laboratory findings into effective human therapies. The complexity of these interconnected pathways also means interventions must be carefully designed to avoid unintended consequences.